Impact of Rituximab on Relapse Rate and Disability in Neuromyelitis Optica
Multiple Sclerosis Journal（2011）
Key words
CD19/20,disease modifying therapies,immune suppressant,monoclonal antibody,neuromyelitis optica,rituximab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined